Biosimilars Are Being Approved but Not Reaching the Market
Just halfway through the year, 2019 has been busy for biosimilars, with new guidance and approvals but also the loss of a big advocate of biosimilars from the FDA.
Just halfway through the year, 2019 has been busy for biosimilars, with new guidance and approvals but also the loss of a big advocate of biosimilars from the FDA. In this episode of Managed Care Cast, Kelly Davio, senior editor of The Center for Biosimilars®, a sister site of The American Journal of Managed Care®, discusses new approvals; what the loss of Scott Gottlieb, MD, as FDA commissioner means; the reality of pay-for-delay deals; and more.
Editor's note: since this conversation was recorded, 2 additional biosimilars, both anticancer agents, have launched in the United States.
Learn more about biosimilars at
Listen above or through one of these podcast services:
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
Transforming Addiction Care: From Stigma to SupportSeptember 16th 2025
- Navigating the Alzheimer Disease Blood Test Revolution
September 9th 2025
- AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025
